Human Immunodeficiency Virus

Immunology·MeSH: Acquired Immunodeficiency Syndrome

24 drugs in development·10 companies·9 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
darunavir	Mylan II B.V. (MYL)
etravirine	Amneal Pharmaceuticals, Inc. (AMRX)
fosamprenavir	Mylan II B.V. (MYL)
nevirapine	Mylan II B.V. (MYL)

Phase 3(5)

Drug	Company
Doravirine	Merck & Co., Inc. (MRK)
Emtricitabine/tenofovir disoproxil	Merck & Co., Inc. (MRK)
ISL	Merck & Co., Inc. (MRK)
MK-8527	Merck & Co., Inc. (MRK)
ULO	Merck & Co., Inc. (MRK)

Phase 2(6)

Drug	Company
2 NRTIs	Merck & Co., Inc. (MRK)
BIC/FTC/TAF	Merck & Co., Inc. (MRK)
Combined LAI Treatment	COLLEGIUM PHARMACEUTICAL, INC (COLL)
DOR/3TC/TDF	Merck & Co., Inc. (MRK)
ISL/ULO	Merck & Co., Inc. (MRK)
Vorinostat	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(6)

Drug	Company
hb-500	HOOKIPA Pharma Inc. (HOOK)
hb-502	HOOKIPA Pharma Inc. (HOOK)
MGD014	UNITED THERAPEUTICS Corp (UTHR)
MGD014	MACROGENICS INC (MGNX)
MGD020	MACROGENICS INC (MGNX)
MGD020	UNITED THERAPEUTICS Corp (UTHR)

Phase 1/Phase 2(1)

Drug	Company
IMC-M113V	Immunocore Holdings plc (IMCR)

Phase 2/Phase 3(1)

Drug	Company
PRO 140	CytoDyn Inc. (CYDY)

Phase 4(1)

Drug	Company
bictegravir/emtricitabine/tenofovir alafenamide	GH Research PLC (GHRS)

BioSniper tracks 24 drugs in development for Human Immunodeficiency Virus across 10 companies.

There are 9 clinical trials targeting Human Immunodeficiency Virus tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.